The overall goal of this UT MDACC SPORE is to facilitate innovative research in the prevention, detection, and treatment of ovarian cancer leading to the elimination of this disease as a major health problem. Our Cancer Center contains a unique concentration of talented investigators who are dedicated to clinical, translational, and funda mental ovarian cancer research. Multi-disciplinary care is provided to a large number of patients. For this SPORE, we have assembled an exceptional group of investigators from nine Universities complement ing the faculty at MDACC. Our institution has given high priority to the Sandra G. Davis Ovarian Cancer Research Program through recruitment, salary supports, clinical facilities, laboratory space and philanthropic funds. Over the last three years, the Program has instituted faculty recruitment, strengthened the research infrastructure, and funded seven pilot projects. We are now poised to take advantage of the rapid increase in the understanding of ovarian cancer at a molecular and cellular level. Funding of this SPORE will enhance our ability to translate insights from ovarian cancer biology to more effective prevention, detection, and treatment of ovarian cancer. The SPORE includes four projects that deal with (1) chemoprevention of ovarian cancer, (2) anti-angiogenesis therapy, (3) therapy with E1A, and (5) PI3 kinase as a target for therapy. Three Cores (Administra tion, Biostatistics and Pathology) will facilitate completion of the proposed projects. Career development funds will further strengthen our faculty and pilot projects will provide preliminary data for peer-reviewed funding. This SPORE will provide a critical component of a larger effort to develop effective strategies for chemoprevention, early detection, molecular profiling and therapeutics, bio- immunotherapy, high dose therapy, individualized therapy, supportive care, and community awareness.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA083639-05S1
Application #
6936161
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Arnold, Julia T
Project Start
1999-09-30
Project End
2005-08-31
Budget Start
2003-09-01
Budget End
2005-08-31
Support Year
5
Fiscal Year
2004
Total Cost
$1,150,000
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Yuan, Jiao; Hu, Zhongyi; Mahal, Brandon A et al. (2018) Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. Cancer Cell 34:549-560.e9
Liu, Xiaojun; Jiang, Yingjun; Nowak, Billie et al. (2018) Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations. Cancer Chemother Pharmacol 81:255-267
Haemmerle, Monika; Stone, Rebecca L; Menter, David G et al. (2018) The Platelet Lifeline to Cancer: Challenges and Opportunities. Cancer Cell 33:965-983
Allen, Julie K; Armaiz-Pena, Guillermo N; Nagaraja, Archana S et al. (2018) Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. Cancer Res 78:3233-3242
Umamaheswaran, Sujanitha; Dasari, Santosh K; Yang, Peiying et al. (2018) Stress, inflammation, and eicosanoids: an emerging perspective. Cancer Metastasis Rev 37:203-211
Wang, Jue; Zhao, Wei; Guo, Huifang et al. (2018) AKT isoform-specific expression and activation across cancer lineages. BMC Cancer 18:742
Huang, Yan; Hu, Wei; Huang, Jie et al. (2018) Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther 17:464-473
Yang, Hailing; Mao, Weiqun; Rodriguez-Aguayo, Cristian et al. (2018) Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. Clin Cancer Res 24:5072-5084
Rhyasen, Garrett W; Yao, Yi; Zhang, Jingwen et al. (2018) BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors. PLoS One 13:e0200826
Chen, Jian; Zaidi, Sobia; Rao, Shuyun et al. (2018) Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-? Pathway. Gastroenterology 154:195-210

Showing the most recent 10 out of 648 publications